The other face of TLR3: A driving force of breast cancer stem cells

Activation of TLR3 has long been studied in the field of anticancer immunotherapy. Our recent work revealed that TLR3 also promotes the induction of breast cancer stem cells (CSCs) through co-activation of β-catenin and NF-κB signaling. Targeting these 2 pathways simultaneously instead of individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Deyong, Wang, Lisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905417/
https://www.ncbi.nlm.nih.gov/pubmed/27308515
http://dx.doi.org/10.4161/23723556.2014.981443
_version_ 1782437256597864448
author Jia, Deyong
Wang, Lisheng
author_facet Jia, Deyong
Wang, Lisheng
author_sort Jia, Deyong
collection PubMed
description Activation of TLR3 has long been studied in the field of anticancer immunotherapy. Our recent work revealed that TLR3 also promotes the induction of breast cancer stem cells (CSCs) through co-activation of β-catenin and NF-κB signaling. Targeting these 2 pathways simultaneously instead of individually allows for effective inhibition of CSCs that are enhanced by TLR3 activation.
format Online
Article
Text
id pubmed-4905417
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49054172016-06-15 The other face of TLR3: A driving force of breast cancer stem cells Jia, Deyong Wang, Lisheng Mol Cell Oncol Author's View Activation of TLR3 has long been studied in the field of anticancer immunotherapy. Our recent work revealed that TLR3 also promotes the induction of breast cancer stem cells (CSCs) through co-activation of β-catenin and NF-κB signaling. Targeting these 2 pathways simultaneously instead of individually allows for effective inhibition of CSCs that are enhanced by TLR3 activation. Taylor & Francis 2015-06-05 /pmc/articles/PMC4905417/ /pubmed/27308515 http://dx.doi.org/10.4161/23723556.2014.981443 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Jia, Deyong
Wang, Lisheng
The other face of TLR3: A driving force of breast cancer stem cells
title The other face of TLR3: A driving force of breast cancer stem cells
title_full The other face of TLR3: A driving force of breast cancer stem cells
title_fullStr The other face of TLR3: A driving force of breast cancer stem cells
title_full_unstemmed The other face of TLR3: A driving force of breast cancer stem cells
title_short The other face of TLR3: A driving force of breast cancer stem cells
title_sort other face of tlr3: a driving force of breast cancer stem cells
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905417/
https://www.ncbi.nlm.nih.gov/pubmed/27308515
http://dx.doi.org/10.4161/23723556.2014.981443
work_keys_str_mv AT jiadeyong theotherfaceoftlr3adrivingforceofbreastcancerstemcells
AT wanglisheng theotherfaceoftlr3adrivingforceofbreastcancerstemcells
AT jiadeyong otherfaceoftlr3adrivingforceofbreastcancerstemcells
AT wanglisheng otherfaceoftlr3adrivingforceofbreastcancerstemcells

Ejemplares similares